Wegovy 7mg: what it is and where it fits in your treatment

Is there actually a Wegovy 7mg dose?

Not precisely. Semaglutide for weight management (sold as Wegovy) follows a fixed titration ladder, and no rung on that ladder is labelled 7mg. The dose you are likely thinking of is 7.2mg, which the MHRA first authorised in January 2026 as a higher maintenance option, initially supplied as three 2.4mg pens taken in the same week. On 14 April 2026, the regulator approved a dedicated single-dose 7.2mg pen: one weekly injection, auto-dosing mechanism, covered needle that locks after use. Significantly more straightforward to use than the three-pen arrangement.

This matters because 7.2mg is the highest dose in the Wegovy range, not an intermediate one. It is not a routine titration step that most patients reach automatically; it sits above the 2.4mg maintenance dose that the standard 2.4mg schedule has always ended on. Your prescriber decides whether moving to 7.2mg is clinically appropriate for you individually. If you want a clear map of how all the Wegovy mg strengths relate to each other across the full range, the full Wegovy dose guide covers each stage.

One thing to hold on to: a higher dose is not automatically a better one for every person. Dose decisions balance efficacy against tolerability, and that balance is individual.

Who is the 7.2mg dose licensed for, and does the eligibility differ?

The April 2026 MHRA approval for the single-dose 7.2mg pen carries a specific eligibility condition: it is licensed for adults with a BMI of 30 or above. The lower threshold (BMI 27 to 29.9 alongside at least one weight-related health condition) that applies to other Wegovy strengths does not extend to the 7.2mg pen. Lower BMI thresholds also apply for some ethnic backgrounds under UK guidance, though that adjustment operates at the standard licensing level rather than the 7.2mg-specific indication.

Beyond BMI, the same considerations that govern Wegovy prescribing more broadly apply here. A prescriber will look at your medical history, any conditions that would make semaglutide unsuitable, and how you have responded to earlier doses. If you are already established on 2.4mg and have not reached a satisfactory response, the conversation about 7.2mg starts there. It is not a first-prescription option; the titration always begins at the 1mg starting phases before stepping through the intermediate strengths and moves up over several months, as the Wegovy treatment overview explains.

The 7.2mg dose is not currently available on the NHS. NICE has not appraised it separately, and NHS access to semaglutide for weight management remains within specialist services under NICE technology appraisal TA875. Private prescribing is the route available at this stage.

What do the trial results for this strength actually show?

The evidence base for 7.2mg semaglutide comes from trials that examined this higher dose after participants had completed the standard 2.4mg titration pathway. Results reported around 20.7% average weight loss over 72 weeks, notably higher than the approximately 15% average seen in the STEP 1 trial at 2.4mg, which was published in the New England Journal of Medicine and remains a cornerstone of semaglutide's evidence base. The 7.2mg figure closes much of the gap with tirzepatide's headline results at 15mg.

It is worth being precise about what "average" means here. Some people in trials lost considerably more; others less. Weight loss with any GLP-1 medicine is shaped by biology, adherence, diet and activity, not by the dose number alone. Clinical trials show what is possible in a controlled setting; a prescriber helps you understand what is realistic for your circumstances.

Side effects at 7.2mg follow the same gastrointestinal pattern seen across the Wegovy range (nausea, loose stools, reflux) and were generally most noticeable after dose increases, often easing within a couple of weeks. Reporting any persistent or severe symptoms to your prescriber or via the MHRA Yellow Card scheme is part of responsible use of any new medicine.

How does nume handle prescribing and availability at this dose?

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber on the day it is submitted, a clinician reads your answers, not software. If a 7.2mg dose is part of your conversation, the prescriber will consider your treatment history and current health before deciding whether it is appropriate. No specific dose or pen format is guaranteed in advance of that assessment; the prescriber confirms what is available and suitable at the point of your consultation.

For people exploring the treatment for the first time, starting at 7.2mg is not the route. The titration schedule begins lower, and patients building toward this strength typically do so over several months, passing through the 2mg Wegovy stage as part of the gradual increase toward maintenance. If you are transferring from another provider already on a higher dose, bringing evidence of your current treatment is part of the process. Orders placed before noon on working days are dispatched the same day once clinically approved, with free tracked DPD delivery the next working day, the pen arrives before most people need to rearrange their morning routine.

If you are weighing up whether semaglutide is the right treatment for your situation, or how it compares with other licensed options, our weight-loss treatment overview sets out the full picture. When you are ready, check your eligibility with a free consultation, a prescriber will guide the dose conversation from there.